Recently I was reading an article in Fierce Biotech site, It had listed down around 16 companies which went for liquidation for reasons ranging from poor clinical data to investors not bailing out.........Most of the companies which went into so called Biotech graveyard rather were focusing on host of metabolic, pain and blood related area's.....Those were the days in early 70's and 80's when maximum amount of work had been carried out in metabolic disorders, then cardiovascular and pain .......Now what I have observed is there is lot MAb race happening not only in United states and across the globe, so what I feel is these innovative companies before rolling out should do their further SWOT in specific therapeutic area they want to venture...How much money they will be able to get from market so that they are able to sustain themselves till Phase III studies ......what do u say about this?
I have read somewhere that innovative companies all more technology driven than the opportunites in the market.
ReplyDelete